For the quarter ending 2025-12-31, CVAT had $1K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net income (loss) | -476 | -258 | -113 |
| Depreciation | - | - | 0 |
| Fair value of common stock issued for services | 244 | - | 195 |
| Fair value of common stock issued for services | - | - | 6 |
| Fair value of warrants granted for services | 0 | - | - |
| Gain on patent assignment | 0 | - | -880 |
| Accounts receivable | -5 | -5 | 10 |
| Prepaid expenses | 0 | -13 | 11 |
| Operating lease right of use asset | 0 | 0 | 42 |
| Accounts payable and accrued expenses | 45 | 21 | 0 |
| Accrued payroll and payroll taxes related parties | - | 0 | 11 |
| Customer advances | - | - | 0 |
| Operating lease liability | 0 | 0 | -46 |
| Net cash used in operating activities | -182 | -219 | -806 |
| Proceeds from patent assignment | 0 | - | 880 |
| Net cash provided by investing activities | 0 | - | 880 |
| Proceeds from convertible note payable | 10 | - | - |
| Proceeds from common stock units | 173 | - | - |
| Repayment of note payable | 0 | 0 | 4 |
| Net cash provided by (used in) financing activities | 183 | 0 | -4 |
| Net (decrease) increase in cash and cash equivalents | 1 | -219 | 70 |
| Cash and cash equivalents at beginning of period | 30 | 249 | 179 |
| Cash and cash equivalents at end of period | 31 | 30 | 249 |
Cavitation Technologies, Inc. (CVAT)
Cavitation Technologies, Inc. (CVAT)